Medigene Immunotherapies Gmbh

Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt

Max-delbruck-centrum Fur Molekulare Medizin in Der Helmholtz-gemeinschaft

Regeneron Pharmaceuticals, Inc.

Zentrum München-deutsches Forschungszentrum Für Gesundheit Und Umwelt (gmbh)

Christian Ellinger

Dolores Schendel

Carina Wehner

Slavoljub Milosevic

Wolfgang Uckert

Daniel Sommermeyer

Felix Lorenz

Susanne Wilde

Jasdeep Mann

Manon Weis

Aline Bracher

Geoffrey Parsons

Geoffrey Blackburn Parsons

The present invention relates to an isolated T cell receptor (TCR) specific for MAGE-A4 and a polypeptide comprising a functional portion of the TCR. Further implicated are a multivalent TCR complex, a nucleic acid encoding a TCR, a cell expressing the TCR and a pharmaceutical composition comprising the TCR. The invention also refers to the TCR for use as a medicament, in particular to the TCR for use in the treatment of cancer.

Mage A4 T cell receptors

The present invention relates to the field of immunotherapy, in particular, to adoptive T cell therapy, T cell receptor (TCR) gene therapy and vaccination. The invention provides a method for preparing a nucleic acid encoding the TCR alpha chain construct (TRA) and TCR beta chain construct (TRB) of a TCR construct specific for an epitope from an antigen presented on major histocompatibility complex (MHC), comprising contacting T cells isolated from a donor with a library of artificial antigen presenting cells (APC) comprising cells expressing all MHC I or MHC II alleles present in the donor, preferably, in K562 cells. The TCR construct can be expressed in a T cell, which is useful for adoptive T cell therapy, e.g., of cancer, viral infections or autoimmune diseases. The invention further provides a method for identifying the epitope recognized by said TCR. Immunogenic epitopes recognized by said TCRs can be used to develop vaccine formulations to induce antigen-specific T cell immunity in patients. The invention further provides pairs of two TCR constructs and respective immunogenic epitopes obtained by the method of the invention, wherein the epitopes are from human papillomavirus (HPV) 16 (also designated alphapapillomavirus 9) oncoprotein E5 and human cytomegalovirus (CMV) protein pp65.

Method of detecting new immunogenic T cell epitopes and isolating new antigen-specific T cell receptors by means of an MHC cell library

The present invention covers an isolated T cell receptor (TCR) specific for one allelic variant of minor histocompatibility antigen 1 (HA-1), in particular the allelic variant HA-1. An isolated polypeptide comprising a functional portion of the TCR is also described. Moreover, a multivalent TCR complex, nucleic acid molecules, vectors, cells, antibodies as well as medical uses that relate to the TCR are defined.

HA-1 specific T cell receptors and their use

The present invention relates to the field of biotechnology. Specifically, the invention provides antigen-specific T-cell receptors (TCRs). Further, the invention encompasses polynucleotides encoding the same and vectors comprising said polynucleotides. Host cells comprising the molecules of the invention are also provided. Moreover, the invention provides means and methods for diagnostics and therapy, in particular of cancer.

T cell receptors and uses thereof

The present invention contemplates methods for the generation of human antigen-specific T lymphocytes. The methods employ MHC class-II targeting signals fused to an antigen or fragment thereof to obtain MHC class presentation of RNA coded proteins. Accordingly, the present invention concerns expression vectors comprising MHC class-II targeting signal and at least one antigen or fragment thereof and its use for the in vitro generation of antigen-specific T lymphocytes. T cell clones and T cell receptors (TCRs) specific for tumor antigens or viral antigens are also described.

Generation of antigen-specific TCRs

The present invention contemplates dendritic cell compositions. The dentritic cell compositions employ MHC class-II targeting signals fused to an antigen or fragment thereof to obtain MHC II presentation of the antigen or fragment thereof. In particular, the invention refers to a dendritic cell vaccine comprising dendritic cells expressing a MHC class-II targeting signal fused to an antigen or fragment thereof. Dendritic cell vaccines for the stimulation of an immune response against melanoma-associated antigen are also described.

Dendritic cell composition

The invention relates to a library for the expression of all functional TCR types comprising 45 TCR constructs each encoding one of the 45 different TCR &#x3b1; chains and 47 TCR constructs each encoding one of the 47 different TCR &#x3b2; chains, wherein each of the 45 TCR constructs encoding one of 45 different TCR &#x3b1; chain comprises the following building blocks one of the variable AV segments AVseg1 to AVseg45, and a constant AC segment, and wherein each of the 47 TCR constructs encoding one of 47 different TCR &#x3b2; chains comprises one of the variable BV segments BVseg1 to BVseg47, and a constant BC segment.

Growing community of inventors

Munich, Germany

Christian Ellinger